30例急性心肌梗死溶栓治疗临床分析

目的探讨尿激酶静脉溶栓治疗急性心肌梗死的临床效果及安全性,并总结治疗经验。方法回顾性分析笔者所在医院2011年1～12月采用尿激酶溶栓治疗的30例急性心肌梗死患者资料,观察再通情况、并发症发生及患者预后情况。结果 30例急性心肌梗死患者经尿激酶溶栓治疗后再通率为93.3%,其中,发病<6h内溶栓的再通率为100.0%;6～12h再通率为88.9%,>12～24h再通率为33.3%。治疗过程中出现并发症4例,并发症发生率为13.3%,死亡2例,死亡率为6.7%,其中1例死于心力衰竭,1例为并发室颤最终抢救无效死亡。结论尿激酶静脉溶栓治疗急性心肌梗死再通率高,并发症发生率低,有效降低病死率;且溶栓距发病时间越短,冠状动脉的再通率则越高,疗效越好。

Clinical analysis of thrombolysis treatment in 30 cases with acute myocardial infarction

Objective To investigate the clinical efficacy and safety of intravenous urokinase in thrombolytic therapy in acute myocardial infarction.Methods The clinical dates of 30 cases with acute myocardial infarction used by urokinase thrombolytic therapy in our hospital from January 2011 to December 2011 were analyzed retrospectively.And the recanalization,complication and prognosis of the patients were observed.Results After urokinase thrombolytic treatment,the recanalization rate of 30 patients with acute myocardial infarction was 93.3%,among 100.0% within 6 hours,88.9% from 6 hours to 12 hours,33.3% above from 12 hours to 24 hours.4 cases occurred complications during the treatment,the rate of complication was 13.3%,and 2 cases died,the death rate was 6.7%,of which 1 case died of heart failure,1 case died of ventricular fibrillation.Conclusion Intravenous thrombolytic therapy in acute myocardial infarction has a high reperfusion rate,low complication rate and low death rate.Shorter time from onset to thrombolysis can increase the recanalization rate of coronary artery and curative effect.